一種新的癌癥疫苗顯示能100%成功治療老鼠身體內(nèi)的惡性黑色素瘤。
Researchers at Scripps Research Institute in La Jolla, Calif., and the University of Texas in Dallas, gave mice suffering from melanoma a cancer immunotherapy drug called anti-PD-L1, which prevents tumor cells from attacking their immune systems. The study found that rodents who were also given Diprovocim, a chemical compound that’s meant to galvanize the immune system, had a 100 percent survival rate.
加州拉霍亞市斯克里普斯研究所和達(dá)拉斯德州大學(xué)的研究人員給患有黑色素瘤的老鼠注射了一種名為PD-L1的癌癥免疫治療藥物,這種藥物可以防止腫瘤細(xì)胞攻擊它們的免疫系統(tǒng)。研究發(fā)現(xiàn),同時(shí)被注射一種叫Diprovocim的化學(xué)物質(zhì)的老鼠有100%的存活率,Diprovocim可以刺激免疫系統(tǒng)。
And attempts to re-introduce cancer tumors in these vaccinated mice failed.
而且被接種疫苗的老鼠沒(méi)法再被重新引入癌癥腫瘤。
While more research needs to be done to determine the vaccine’s effectiveness in humans, researchers are hopeful about their findings.
雖然還需要做更多的研究來(lái)確定疫苗是否對(duì)人類(lèi)有效,但研究人員對(duì)他們的發(fā)現(xiàn)充滿希望。
“Just as a vaccine can train the body to fight off external pathogens, this vaccine trains the immune system to go after the tumor,” Dale Boger, a chemist at Scripps, wrote in a press release. “This co-therapy produced a complete response — a curative response — in the treatment of melanoma.”
斯克里普斯的化學(xué)家戴爾.博格在一份新聞稿中寫(xiě)道:“就像疫苗可以訓(xùn)練身體抵抗外部病原體一樣,這種疫苗也可以訓(xùn)練免疫系統(tǒng)去對(duì)付腫瘤。這種聯(lián)合治療在治療黑素瘤中產(chǎn)生了完全緩解,即治療反應(yīng)。”
According to the American Cancer Society, more than 9,000 people die of melanoma every year, and it accounts for about 1 percent of skin cancer diagnoses in the US.
據(jù)美國(guó)癌癥協(xié)會(huì)統(tǒng)計(jì),每年有9000多人死于黑素瘤,美國(guó)診斷出的皮膚癌患中,黑素瘤約占1%。